Large-Scale Oligonucleotide Synthesis Service Market Size and Share Analysis - Growth Trends and Forecasts (2025-2032)

Market Size and Trends

The Large-Scale Oligonucleotide Synthesis Service market is estimated to be valued at USD 1.45 billion in 2025 and is expected to reach USD 3.18 billion by 2032, growing at a compound annual growth rate (CAGR) of 11.6% from 2025 to 2032. This robust growth trajectory underscores the expanding adoption of oligonucleotide synthesis in various applications such as therapeutics, diagnostics, and research, driven by advancements in biotechnology and increasing demand for personalized medicine.

The market trend for large-scale oligonucleotide synthesis services is being shaped by significant innovations in synthesis technologies, enhancing efficiency, accuracy, and scalability. There is a growing emphasis on automated and high-throughput synthesis platforms to meet rising demand, particularly in gene editing, mRNA vaccines, and antisense therapies. Additionally, strategic collaborations between biotechnology companies and service providers further fuel market expansion. Increasing investment in research and development aimed at reducing synthesis costs and improving product quality also supports sustained market momentum.

Segmental Analysis:

By Synthesis Technology: Dominance of Phosphoramidite Synthesis Driven by Efficiency and Versatility

In terms of By Synthesis Technology, Phosphoramidite Synthesis contributes the highest share of the market owing to its well-established methodology, scalability, and compatibility with high-throughput synthesis processes. This technology enables the rapid and precise assembly of oligonucleotide chains through a series of chemically controlled steps, allowing for high purity and yield. The efficiency of the phosphoramidite approach makes it particularly suited for large-scale production, which is a critical factor as demand increases within pharmaceutical and biotechnology sectors. Additionally, the adaptability of this synthesis method to automation reduces production time and cost, further propelling its widespread adoption. Other synthesis methods, like enzymatic and solid-phase synthesis, have their niches but generally face limitations either in terms of throughput or cost-effectiveness for large-scale manufacturing. The phosphoramidite process also boasts robust compatibility with a diverse set of oligonucleotide modifications, which are increasingly important for optimized therapeutic and diagnostic applications. This flexibility appeals to end-users requiring customized oligonucleotides with enhanced stability or specific functional groups, thereby reinforcing phosphoramidite synthesis as the preferred choice. The market dynamics further favor this segment because of the continuous technological improvements in phosphoramidite chemistry that enhance product quality and broaden the range of oligonucleotide lengths producible within a single synthesis cycle. Overall, the dominance of phosphoramidite synthesis is driven by its proven reliability, cost efficiency, and versatility across various downstream applications.

By Application: Therapeutics Segment Leading Through Rising Demand for Precision Medicine

By Application, Therapeutics commands the largest share of the large-scale oligonucleotide synthesis service market, fueled primarily by the growing prominence of oligonucleotide-based therapies such as antisense oligonucleotides, siRNA, and aptamers. These therapeutic modalities are instrumental in targeting previously "undruggable" genetic pathways, opening a vast frontier in treating genetic disorders, cancers, and viral infections. The ability of oligonucleotide therapeutics to precisely modulate gene expression at the RNA level positions them as revolutionary alternatives to traditional small molecules or biologics. Increasing R&D investments and successful regulatory approvals of new oligonucleotide-based drugs contribute significantly to the segment's growth. Additionally, the personalized medicine trend, driven by advances in genomics and companion diagnostics, relies heavily on rapid and cost-effective synthesis of patient-specific oligonucleotides, amplifying demand within the therapeutics space. The scalability of synthesis technologies aligned with stringent quality and purity requirements also supports large-scale manufacturing to meet clinical and commercial needs. Alongside therapeutics, related applications such as diagnostics and agricultural biotechnology are expanding but do not match the volume and investment level observed in therapeutics. Thus, therapeutic applications dominate due to the urgent need for novel treatments with high specificity and minimal off-target effects, making oligonucleotide synthesis services critical for the development pipeline of next-generation medicines.

By Oligonucleotide Length: Preference for Short Oligonucleotides Reflecting Demand for Targeted, Cost-Effective Solutions

By Oligonucleotide Length, Short Oligonucleotides (<50 bases) contribute the highest share of the market, driven by their broad utility across therapeutic, diagnostic, and research applications. The preference for shorter oligonucleotides is attributed to their relatively straightforward synthesis and purification processes, which allow for higher throughput and lower manufacturing costs. Short oligonucleotides effectively meet the needs of many antisense and siRNA drugs where sequences typically range within this length bracket to ensure efficient cellular uptake and minimal immunogenicity. Furthermore, in diagnostic assays, short probes are widely employed due to their rapid hybridization kinetics and specificity, providing accurate and early detection of genetic markers or pathogens. The growing reliance on these shorter constructs in multiplex assays and high-throughput screening formats further sustains the demand. From a manufacturing perspective, shorter oligonucleotides present fewer challenges in terms of synthesis fidelity and product stability compared to longer sequences, making them preferable for large-scale production. Despite the emerging interest in medium and long oligonucleotides for specialized applications, the cost-effective nature and versatility of short oligonucleotides maintain their dominant market position. Their pivotal role in enabling accessible, scalable, and targeted molecular tools forms the backbone of the current oligonucleotide synthesis landscape.

Regional Insights:

Dominating Region: North America

In North America, the dominance in the Large-Scale Oligonucleotide Synthesis Service market is driven by a mature biotechnology and pharmaceutical ecosystem, abundant research funding, and a strong presence of leading companies specializing in oligonucleotide synthesis and related services. The region benefits from extensive government support through initiatives aimed at advancing genomics, personalized medicine, and synthetic biology. Regulatory frameworks promote innovation while maintaining rigorous quality standards, attracting global clients to North American service providers. Major players, such as Integrated DNA Technologies (IDT), GenScript, and Twist Bioscience, have established advanced synthesis platforms and robust supply chains, enabling large-scale production capabilities that fulfill demand from both clinical and research sectors. Additionally, the well-developed healthcare infrastructure and collaborations between academic institutions and industry further reinforce North America's position as the market leader.

Fastest-Growing Region: Asia Pacific

Meanwhile, the Asia Pacific exhibits the fastest growth in the Large-Scale Oligonucleotide Synthesis Service market, fueled by rising investment in biotechnology and pharmaceutical manufacturing, expanding research infrastructure, and government incentives supporting biopharmaceutical innovation. Countries like China, Japan, and South Korea have significantly increased funding for genomic research and synthetic biology, fostering an environment conducive to growth. The competitive labor costs and growing contract research organization (CRO) industry also attract outsourcing of oligonucleotide synthesis tasks to this region. Leading companies such as BGI Genomics (China), Macrogen (South Korea), and FASMAC (Japan) are expanding their synthesis capacity and technological capabilities, helping meet surging demand domestically and internationally. Trade dynamics, including improving intellectual property regimes and free trade agreements, further enhance the region's appeal as a cost-effective, yet high-quality, alternative to western service providers.

Large-Scale Oligonucleotide Synthesis Service Market Outlook for Key Countries

United States

The United States continues to lead the market with significant investment in cutting-edge oligonucleotide synthesis technologies and extensive collaborations between biotech startups and established pharmaceutical companies. Key players like IDT and Twist Bioscience constantly innovate to deliver high-throughput, customizable oligo synthesis solutions, meeting diverse research and therapeutic needs. Government initiatives focused on precision medicine and the development of nucleic acid therapeutics spur demand, making the U.S. a hub for advancements in this market.

China

China's oligonucleotide synthesis market is rapidly evolving with strong government backing for biopharma innovation and synthetic biology initiatives. Companies such as BGI Genomics and Synbio Technologies are expanding their production capabilities to serve both local and global clients. The growing CRO sector and increasing export of biotechnological services further propel market growth, supported by favorable policies aimed at attracting foreign investment and fostering homegrown technological development.

Germany

Germany remains a key player in Europe's oligonucleotide synthesis landscape, with a strong industrial base in pharmaceutical manufacturing and robust R&D infrastructure. Companies like Eurofins Genomics and LGC Group leverage advanced technologies to provide large-scale synthesis services for academic research and drug development. The country's stringent quality regulations and emphasis on innovation ensure high standards in service offerings, contributing to Germany's significant market presence.

Japan

Japan's market is distinguished by its integration of advanced automation and precision technology in oligonucleotide synthesis. Firms such as FASMAC and Takara Bio contribute extensively to large-scale production, supporting both domestic pharmaceutical companies and international collaborations. The government's focus on regenerative medicine and nucleic acid therapeutics, along with investments in next-generation research facilities, underpins the country's growing significance within the Asia Pacific region.

United Kingdom

The United Kingdom holds a strategic position in Europe's oligonucleotide synthesis service market, driven by its vibrant biotech sector and strong academic-industry partnerships. Companies like Oxford Genetics and ATDBio are notable contributors, offering tailored synthesis solutions that fuel research in gene editing and therapeutic development. Supportive government policies and funding programs geared towards genomic innovation sustain competitiveness and encourage expansion in synthesis capabilities.

Market Report Scope

Market Segmentation

Synthesis Technology Insights (Revenue, USD, 2020 - 2032)

• Phosphoramidite Synthesis
• Enzymatic Synthesis
• Solid-phase Synthesis
• Liquid-phase Synthesis
• Others

Application Insights (Revenue, USD, 2020 - 2032)

• Therapeutics
• Diagnostics
• Agricultural Biotechnology
• Research & Development
• Others

Oligonucleotide Length Insights (Revenue, USD, 2020 - 2032)

• Short Oligonucleotides (<50 bases)
• Medium Oligonucleotides (50-100 bases)
• Long Oligonucleotides (100 bases)
• Others

Regional Insights (Revenue, USD, 2020 - 2032)

• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa

Key Players Insights

• Advanced OligoTech Inc.
• SynBio Solutions Ltd.
• Nexus Nucleics Pvt. Ltd.
• GenPrime Synthesis Services
• BioSynth Systems AG
• HelixGen Pharma
• OligoWorks Corporation
• NucleoNext Technologies
• Precision Gene Synthesis Inc.
• Cyclic DNA Synthesis Ltd.
• GeneCraft Ltd.
• PolyNucleotide Labs